UK pharma major AstraZeneca (LSE: AZN) today revealed that, this week, it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across England and Wales.
Tagrisso (osimertinib) received a positive recommendation from the NICE for National Health Service (NHS) use as an adjuvant treatment option after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. Following a three-year period within the Cancer Drugs Fund (CDF), this recommendation means that osimertinib has successfully exited the CDF, enabling full baseline commissioning within NHS England for this patient population.
Also, Imfinzi (durvalumab) was recommended by the NICE for NHS use in combination with etoposide plus either carboplatin or cisplatin for adults with untreated extensive-stage small cell lung cancer (ES-SCLC).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze